Emergent BioSolutions Gains from Government Contract#
Emergent BioSolutions Inc. (NYSE:EBS) saw its shares rise by 4.5% in after-hours trading on Wednesday. This increase followed the announcement of a significant $54 million contract with the Administration for Strategic Preparedness and Response (ASPR). The contract focuses on delivering CNJ-016, a treatment aimed at smallpox preparedness.
Details of the Contract#
The $54 million contract is part of an existing 10-year agreement with ASPR, which allows for additional doses of Vaccinia Immune Globulin Intravenous (Human). This treatment is specifically designed to address complications that may arise from smallpox vaccinations.
Additional Orders and International Partnerships#
In addition to the ASPR contract, Emergent BioSolutions has also secured $6.6 million in new orders from an international government partner. These orders are for ACAM2000, a smallpox vaccine that is part of the company's medical countermeasures portfolio. This partnership aims to bolster the partner's biodefense strategy against smallpox.
Recent Agreements with Canada#
These announcements come on the heels of Emergent’s recent multi-year agreements with the Government of Canada, which could be valued up to $140 million CAD. These agreements are intended to enhance Canada’s preparedness and response capabilities against biological threats. Notably, over $35 million CAD from these agreements is expected to be received in 2026.
Understanding the Treatments#
CNJ-016 is FDA-approved for treating complications from smallpox vaccination, while ACAM2000 is a live vaccine used for biodefense purposes. Both products play a crucial role in ensuring preparedness against potential smallpox outbreaks.